Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Get Assistance

Get Assistance - Cox Boys
We are here to help people with CF get the insurance coverage they need. Hear how the Foundation helped the Cox family.

Join us on Facebook!  Facebook 
Follow us on Twitter!   Twitter
Follow us on Instagram!  Instagram 
Add us to your circle in Google+!

Google+ 

Subscribe to our channel on YouTube!  YouTube  


 

 

Print  

Inhaled Antibiotic Used to Treat Cystic Fibrosis Shows Positive Results in Clinical Trials

April 23, 2007

Gilead Sciences, Inc. has announced positive results of a clinical trial evaluating the use of an antibiotic treatment for cystic fibrosis patients with pulmonary infections. Aztreonam lysine, an inhaled version of a similar antibiotic already approved by the Food and Drug Administration, was studied on CF patients with Pseudomonas aeruginosa pulmonary infections.

Results from a Phase 3 clinical trial involving 246 volunteers demonstrated that patients receiving a 28-day treatment of inhaled aztreonam lysine experienced significant improvements in pulmonary function and respiratory symptoms when compared to those receiving a placebo. Patients using inhaled aztreonam lysine also could go longer periods of time before needing to use additional inhaled or intravenous antibiotics.

Gilead expects to submit a New Drug Application for aztreonam lysine for inhalation in the second half of 2007. Data from this analysis has not yet been reviewed by the Food and Drug Administration.

The Cystic Fibrosis Foundation is an accredited charity of the Better Business Bureau.